Amarin Corporation (AMRN) Earnings: Q3 2026 Results

The quarter ended September 30, 2026 and Amarin published the results on October 28, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison. Amarin reports EPS two ways: GAAP, under the accounting rules every US filer follows, and non-GAAP, which leaves out items the company considers outside its operating results. The release reconciles the two, and when they diverge, the reconciliation says why.

• EPS is per ordinary share, as Amarin's release reports it. Each Nasdaq-listed ADS has represented 20 ordinary shares since April 11, 2025; per ADS, GAAP EPS was $0.01 against $(0.37) a year earlier, and non-GAAP EPS was $0.08 against $0.19.
• Amarin is incorporated in England and Wales but files U.S. domestic forms (10-Q and 10-K).

Source: Amarin Q3 2026 results, October 28, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How Amarin splits revenue in its own release, under its own labels, for Q3 2026 against Q3 2025. Indented lines are parts of the line above them.

• Amarin's Product revenue, net revenue was $36.9 million in Q3 2026, down 24% from $48.6 million in Q3 2025, 93% of total revenue.
• Amarin's Licensing and royalty revenue revenue was $2.7 million in Q3 2026, up 139% from $1.1 million in Q3 2025, 7% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

From the earnings release

Amarin gives no revenue or EPS outlook. Its release lists FY 2026 expectations of further operating expense reductions in Q4, positive operating cash flow for Q4, about $330 million of cash and investments, and no debt.

In its Q3 2026 release, Amarin said:

“The Company expects U.S. volumes to remain broadly stable for the remainder of FY 2026.”

“The Company expects combined in-market demand across all its global partner markets to continue to grow on a sequential quarterly basis.”

Source: Amarin Q3 2026 release, Oct 28, 2026.

This is the company's own guidance as of Oct 28, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the AMRN forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

GAAP total revenue, net (in millions) and diluted EPS per ordinary share, each as first reported in that quarter's release. Q4 2025 was a net loss of $1.2 million, which rounds to $(0.00) per ordinary share.

We do not hold a confirmed date for Amarin's next report. Companies post the date on their investor relations site a few weeks ahead, usually with the time of the conference call.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Oct 28, 2026

Amarin sells one drug, VASCEPA (VAZKEPA in Europe), the icosapent ethyl capsule for cardiovascular risk reduction. Total net revenue was $39.6 million in Q3 2026, down 20% from $49.7 million. Net product revenue was $36.9 million: $28.5 million in the U.S., $3.7 million in Europe and $4.7 million in the rest of the world. Licensing and royalties added $2.7 million, against $1.1 million. (Amarin Q3 2026 release, Oct 28, 2026)

Amarin's U.S. sales of VASCEPA fell 30%, which it attributed largely to lower net pricing from changes in customer mix driven by continued generic competition. Generic versions of icosapent ethyl have been on the U.S. market since a 2020 court ruling invalidated several of Amarin's patents. Amarin still held a 47% share of the U.S. icosapent ethyl market in the quarter. (Amarin Q3 2026 release, Oct 28, 2026; Amarin Form 10-Q, Q3 2026, Oct 28, 2026)

Outside the U.S., Amarin now sells through partners. Recordati holds an exclusive license and supply agreement covering 59 countries, with patent protection extending through 2039 in those markets. European product revenue fell 9% because last year's third quarter included launch inventory purchases at the start of that partnership, while Amarin estimates in-market demand for VAZKEPA in Europe rose 68%. Rest-of-world sales rose 29%, and licensing and royalty revenue rose 139% on higher partner sales. (Amarin Q3 2026 release, Oct 28, 2026)

Amarin's U.S. sales run through three customers, labelled A, B and C in the 10-Q, which accounted for 30%, 31% and 26% of gross product sales in the first nine months of 2026. VASCEPA/VAZKEPA was commercially available in 22 countries at September 30, 2026, including 11 European countries through Recordati. (Amarin Form 10-Q, Q3 2026, Oct 28, 2026; Amarin Q3 2026 release, Oct 28, 2026)

Amarin reported net income of $245 thousand for Q3 2026, against a net loss of $7.7 million a year earlier, which its CFO called the first profitable quarter in over two years. Per ordinary share, EPS was $0.00 against $(0.02). Per ADS, each of which represents 20 ordinary shares, the 10-Q shows earnings of $0.01 against a loss of $(0.37). (Amarin Q3 2026 release, Oct 28, 2026; Amarin Form 10-Q, Q3 2026, Oct 28, 2026)

Amarin's non-GAAP net income of $1.6 million, or $0.08 per ADS, excludes $1.4 million of stock-based compensation. There was no restructuring charge in Q3 2026, against $9.4 million a year earlier. Total operating expenses fell to $18.5 million from $33.3 million, with SG&A down 27% to $14.3 million after a global restructuring completed in Q2 2026. Cost of goods sold fell 15% to $23.4 million on lower volumes and better API purchasing terms. (Amarin Q3 2026 release, Oct 28, 2026)

Interest income of $2.4 million more than covered the $2.4 million operating loss, leaving pre-tax income of $315 thousand. Amarin ended the quarter with $323.4 million of cash, cash equivalents and short-term investments and no debt, and said it is working with Barclays as its exclusive financial advisor with a mandate to maximize shareholder value. Basic weighted average ordinary shares were 417,766 thousand. (Amarin Q3 2026 release, Oct 28, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

Amarin does not give a revenue or EPS outlook. Its release carries a table of FY 2026 expectations instead: further operating expense reductions in Q4, positive net cash from operating activities in Q4, cash and investments of about $330 million, and remaining debt free. It also said it expects U.S. volumes to remain broadly stable for the rest of 2026 and in-market demand across its partner markets to keep growing quarter to quarter. (Amarin Q3 2026 release, Oct 28, 2026)

A consensus figure is the average of the models published by the analysts who cover Amarin, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones Amarin's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning AMRN is on is AMRN a buy or a sell?, what analysts expect next is on the AMRN forecast, and what the company does is on the Amarin Corporation (AMRN) stock page.

Every number on this page can be traced to a document Amarin published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.